Qui T. Phung
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Qui T. Phung has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
- Corey E. Bakalarski
Department of Proteomic and Genomic Technologies, Genentech, Inc. , South San Francisco, CA 94080
2 shared publications - Ira Mellman
Genentech
2 shared publications - Jennie R. Lill
Department of Microchemistry, Proteomics, and Lipidomics, Genentech, Inc., South San Francisco, California
2 shared publications Aaron Gupta
Department of Physiological Chemistry, Genentech, Inc., South San Francisco, CA 94080
1 shared publication- Ajay Fernandez
Doctor of Osteopathic Medicine Program, Arizona College of Osteopathic Medicine, 19555 59th Ave, Glendale, AZ 85308, United States
1 shared publication - Alison Coady
Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, USA, USA
1 shared publication
Latest Publications
- Open Access
- 6 June 2024
- Published by Taylor & Francis in mAbs
- Vol. 16 (1) , 2362789
Nonclinical immunogenicity risk assessment for knobs-into-holes bispecific IgG 1 antibodies
Bispecific antibodies, including bispecific IgG, are emerging as an important new class of antibody therapeutics. As a result, we, as well as others, have developed engineering strategies designed to facilitate the efficient production of bispecific IgG for clinical development. For example, we have extensively used knobs-into-holes (KIH) mutations to facilitate the heterodimerization of antibody heavy chains and more recently Fab mutations to promote cognate heavy/light chain pairing for efficient in vivo assembly of bispecific IgG in single host cells. A panel of related monospecific and bispecific IgG1 antibodies was constructed and assessed for immunogenicity risk by comparison with benchmark antibodies with known low (Avastin and Herceptin) or high (bococizumab and ATR-107) clinical incidence of anti-drug antibodies. Assay methods used include dendritic cell internalization, T cell proliferation, and T cell epitope identification by in silico prediction and MHC-associated peptide proteomics. Data from each method were considered independently and then together for an overall integrated immunogenicity risk assessment. In toto, these data suggest that the KIH mutations and in vitro assembly of half antibodies do not represent a major risk for immunogenicity of bispecific IgG1, nor do the Fab mutations used for efficient in vivo assembly of bispecifics in single host cells. Comparable or slightly higher immunogenicity risk assessment data were obtained for research-grade preparations of trastuzumab and bevacizumab versus Herceptin and Avastin, respectively. These data provide experimental support for the common practice of using research-grade preparations of IgG1 as surrogates for immunogenicity risk assessment of their corresponding pharmaceutical counterparts.
- 6 June 2024
- Published by Taylor & Francis in mAbs
- Vol. 16 (1) , 2362789
Open AccessNonclinical immunogenicity risk assessment for knobs-into-holes bispecific IgG 1 antibodies
Bispecific antibodies, including bispecific IgG, are emerging as an important new class of antibody therapeutics. As a result, we, as well as others, have developed engineering strategies designed to facilitate the efficient production of bispecific IgG for clinical development. For example, we have extensively used knobs-into-holes (KIH) mutations to facilitate the heterodimerization of antibody heavy chains and more recently Fab mutations to promote cognate heavy/light chain pairing for efficient in vivo assembly of bispecific IgG in single host cells. A panel of related monospecific and bispecific IgG1 antibodies was constructed and assessed for immunogenicity risk by comparison with benchmark antibodies with known low (Avastin and Herceptin) or high (bococizumab and ATR-107) clinical incidence of anti-drug antibodies. Assay methods used include dendritic cell internalization, T cell proliferation, and T cell epitope identification by in silico prediction and MHC-associated peptide proteomics. Data from each method were considered independently and then together for an overall integrated immunogenicity risk assessment. In toto, these data suggest that the KIH mutations and in vitro assembly of half antibodies do not represent a major risk for immunogenicity of bispecific IgG1, nor do the Fab mutations used for efficient in vivo assembly of bispecifics in single host cells. Comparable or slightly higher immunogenicity risk assessment data were obtained for research-grade preparations of trastuzumab and bevacizumab versus Herceptin and Avastin, respectively. These data provide experimental support for the common practice of using research-grade preparations of IgG1 as surrogates for immunogenicity risk assessment of their corresponding pharmaceutical counterparts.
- 15 March 2021
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 118 (12)
Discovery of a caspase cleavage motif antibody reveals insights into noncanonical inflammasome function
Significance: Inflammasomes, cytosolic multicomponent complexes, sense patterns of pathogenesis or metabolic changes and initiate a cellular response via the activation of the inflammatory caspases (iCasps). A more comprehensive substrate analysis for iCasps will greatly improve our understanding of this pathway and provide potential blood-based biomarkers for inflammasome activation in disease. Antibodies typically exhibit high affinity and specificity for a single modification site, in direct contrast to a protease that exhibits a more degenerate recognition profile. Here, we generate antibodies that defy this convention and exhibit a degenerate recognition motif similar to the iCasps and apply these new tools to elucidate hundreds of putative iCasp substrates. Our findings reveal insights into inflammasome function.
- 15 March 2021
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 118 (12)
Discovery of a caspase cleavage motif antibody reveals insights into noncanonical inflammasome function
Significance: Inflammasomes, cytosolic multicomponent complexes, sense patterns of pathogenesis or metabolic changes and initiate a cellular response via the activation of the inflammatory caspases (iCasps). A more comprehensive substrate analysis for iCasps will greatly improve our understanding of this pathway and provide potential blood-based biomarkers for inflammasome activation in disease. Antibodies typically exhibit high affinity and specificity for a single modification site, in direct contrast to a protease that exhibits a more degenerate recognition profile. Here, we generate antibodies that defy this convention and exhibit a degenerate recognition motif similar to the iCasps and apply these new tools to elucidate hundreds of putative iCasp substrates. Our findings reveal insights into inflammasome function.
- Open Access
- 18 February 2021
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 118 (8)
Activation of NF-κB and p300/CBP potentiates cancer chemoimmunotherapy through induction of MHC-I antigen presentation
Significance: T cells recognize their targets via their T-cell receptors (TCRs), which in the case of CD8 + T cells bind to MHC-I:antigen complexes on the surface of target cells. Many cancer cells evade immune recognition and killing by down-regulating MHC-I AgPPM. Here, we show how the histone acetyl transferases p300/CBP together with NF-κB epigenetically regulate expression of MHC-I molecules, immunoproteasome subunits, and peptide transporter to enable proper MHC-I antigen presentation. Notably, this pathway is frequently disrupted in human cancers. We now show that certain chemotherapeutics can augment MHC-I antigen presentation via NF-κB and p300/CBP activation, thereby enhancing cancer cell recognition and killing by effector CD8 + CTLs.
- 18 February 2021
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 118 (8)
Open AccessActivation of NF-κB and p300/CBP potentiates cancer chemoimmunotherapy through induction of MHC-I antigen presentation
Significance: T cells recognize their targets via their T-cell receptors (TCRs), which in the case of CD8 + T cells bind to MHC-I:antigen complexes on the surface of target cells. Many cancer cells evade immune recognition and killing by down-regulating MHC-I AgPPM. Here, we show how the histone acetyl transferases p300/CBP together with NF-κB epigenetically regulate expression of MHC-I molecules, immunoproteasome subunits, and peptide transporter to enable proper MHC-I antigen presentation. Notably, this pathway is frequently disrupted in human cancers. We now show that certain chemotherapeutics can augment MHC-I antigen presentation via NF-κB and p300/CBP activation, thereby enhancing cancer cell recognition and killing by effector CD8 + CTLs.
- Open Access
- 15 January 2020
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 217 (4)
Mutation position is an important determinant for predicting cancer neoantigens
Tumor-specific mutations can generate neoantigens that drive CD8 T cell responses against cancer. Next-generation sequencing and computational methods have been successfully applied to identify mutations and predict neoantigens. However, only a small fraction of predicted neoantigens are immunogenic. Currently, predicted peptide binding affinity for MHC-I is often the major criterion for prioritizing neoantigens, although little progress has been made toward understanding the precise functional relationship between affinity and immunogenicity. We therefore systematically assessed the immunogenicity of peptides containing single amino acid mutations in mouse tumor models and divided them into two classes of immunogenic mutations. The first comprises mutations at a nonanchor residue, for which we find that the predicted absolute binding affinity is predictive of immunogenicity. The second involves mutations at an anchor residue; here, predicted relative affinity (compared with the WT counterpart) is a better predictor. Incorporating these features into an immunogenicity model significantly improves neoantigen ranking. Importantly, these properties of neoantigens are also predictive in human datasets, suggesting that they can be used to prioritize neoantigens for individualized neoantigen-specific immunotherapies.
- 15 January 2020
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 217 (4)
Open AccessMutation position is an important determinant for predicting cancer neoantigens
Tumor-specific mutations can generate neoantigens that drive CD8 T cell responses against cancer. Next-generation sequencing and computational methods have been successfully applied to identify mutations and predict neoantigens. However, only a small fraction of predicted neoantigens are immunogenic. Currently, predicted peptide binding affinity for MHC-I is often the major criterion for prioritizing neoantigens, although little progress has been made toward understanding the precise functional relationship between affinity and immunogenicity. We therefore systematically assessed the immunogenicity of peptides containing single amino acid mutations in mouse tumor models and divided them into two classes of immunogenic mutations. The first comprises mutations at a nonanchor residue, for which we find that the predicted absolute binding affinity is predictive of immunogenicity. The second involves mutations at an anchor residue; here, predicted relative affinity (compared with the WT counterpart) is a better predictor. Incorporating these features into an immunogenicity model significantly improves neoantigen ranking. Importantly, these properties of neoantigens are also predictive in human datasets, suggesting that they can be used to prioritize neoantigens for individualized neoantigen-specific immunotherapies.
- Open Access
- 17 September 2015
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (9) , e0138350
The Staphylococcus aureus ABC-Type Manganese Transporter MntABC Is Critical for Reinitiation of Bacterial Replication Following Exposure to Phagocytic Oxidative Burst
Manganese plays a central role in cellular detoxification of reactive oxygen species (ROS). Therefore, manganese acquisition is considered to be important for bacterial pathogenesis by counteracting the oxidative burst of phagocytic cells during host infection. However, detailed analysis of the interplay between bacterial manganese acquisition and phagocytic cells and its impact on bacterial pathogenesis has remained elusive for Staphylococcus aureus, a major human pathogen. Here, we show that a mntC mutant, which lacks the functional manganese transporter MntABC, was more sensitive to killing by human neutrophils but not murine macrophages, unless the mntC mutant was pre-exposed to oxidative stress. Notably, the mntC mutant formed strikingly small colonies when recovered from both type of phagocytic cells. We show that this phenotype is a direct consequence of the inability of the mntC mutant to reinitiate growth after exposure to phagocytic oxidative burst. Transcript and quantitative proteomics analyses revealed that the manganese-dependent ribonucleotide reductase complex NrdEF, which is essential for DNA synthesis and repair, was highly induced in the mntC mutant under oxidative stress conditions including after phagocytosis. Since NrdEF proteins are essential for S. aureus viability we hypothesize that cells lacking MntABC might attempt to compensate for the impaired function of NrdEF by increasing their expression. Our data suggest that besides ROS detoxification, functional manganese acquisition is likely crucial for S. aureus pathogenesis by repairing oxidative damages, thereby ensuring efficient bacterial growth after phagocytic oxidative burst, which is an attribute critical for disseminating and establishing infection in the host.
- 17 September 2015
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (9) , e0138350
Open AccessThe Staphylococcus aureus ABC-Type Manganese Transporter MntABC Is Critical for Reinitiation of Bacterial Replication Following Exposure to Phagocytic Oxidative Burst
Manganese plays a central role in cellular detoxification of reactive oxygen species (ROS). Therefore, manganese acquisition is considered to be important for bacterial pathogenesis by counteracting the oxidative burst of phagocytic cells during host infection. However, detailed analysis of the interplay between bacterial manganese acquisition and phagocytic cells and its impact on bacterial pathogenesis has remained elusive for Staphylococcus aureus, a major human pathogen. Here, we show that a mntC mutant, which lacks the functional manganese transporter MntABC, was more sensitive to killing by human neutrophils but not murine macrophages, unless the mntC mutant was pre-exposed to oxidative stress. Notably, the mntC mutant formed strikingly small colonies when recovered from both type of phagocytic cells. We show that this phenotype is a direct consequence of the inability of the mntC mutant to reinitiate growth after exposure to phagocytic oxidative burst. Transcript and quantitative proteomics analyses revealed that the manganese-dependent ribonucleotide reductase complex NrdEF, which is essential for DNA synthesis and repair, was highly induced in the mntC mutant under oxidative stress conditions including after phagocytosis. Since NrdEF proteins are essential for S. aureus viability we hypothesize that cells lacking MntABC might attempt to compensate for the impaired function of NrdEF by increasing their expression. Our data suggest that besides ROS detoxification, functional manganese acquisition is likely crucial for S. aureus pathogenesis by repairing oxidative damages, thereby ensuring efficient bacterial growth after phagocytic oxidative burst, which is an attribute critical for disseminating and establishing infection in the host.